Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049307 · ClinicalTrials.gov registry record · Phase 2
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
A Phase 2 study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT02049307 is a Phase 2 study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 108 participants.
The verdict
NCT02049307, a Phase 2 study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential effectiveness of losartan (100mg daily) for reducing inflammation and improving immune recovery.
Interventions
- DRUG Matching placebo
- DRUG Losartan 100mg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2014-10-16 |
| Est. Completion | 2018-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049307
The ClinicalTrials.gov registry entry for NCT02049307 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT02049307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049307 about?
NCT02049307 is a clinical study titled "Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial". The purpose of this study is to evaluate the potential effectiveness of losartan (100mg daily) for reducing inflammation and improving immune recovery.
What is the current status of trial NCT02049307?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2014-10-16. Estimated completion is 2018-12-14.
What interventions are being tested in trial NCT02049307?
The interventions under investigation include: Matching placebo (DRUG), Losartan 100mg daily (DRUG).
Who is sponsoring clinical trial NCT02049307?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.